- Effect of DA-9701 on Colorectal Distension-Induced Visceral Hypersensitivity in a Rat Model
-
Kim ER, Min BH, Lee TH, Son M, Rhee PL
- KMID: 1792361
- Gut Liver.
- 2014 Jul;8(4):388-393.
BACKGROUND/AIMS: DA-9701 is a newly developed drug made from the vegetal extracts of Pharbitidis semen and Corydalis tuber. The aim of this study was to evaluate the effect of DA-9701... -
- CITED
-
- Close
- SHARE
-
- Close
- Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
-
Bae S, Lee KJ, Kim YS, Kim KN
- KMID: 2160605
- J Korean Med Sci.
- 2015 Jun;30(6):757-762.
- doi: 10.3346/jkms.2015.30.6.757
Small intestinal bacterial overgrowth (SIBO) can partly explain irritable bowel syndrome (IBS), and rifaximin has been observed to improve abdominal symptoms in nonconstipated IBS patients. However, there are few reports... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study
-
Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH, IBD Study Group of the Korean Association for the Study of the Intestinal Diseases
- KMID: 2427155
- Yonsei Med J.
- 2016 Nov;57(6):1376-1385.
- doi: 10.3349/ymj.2016.57.6.1376
PURPOSE: Infliximab is currently used for the treatment of active Crohn's disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of... -
- CITED
-
- Close
- SHARE
-
- Close
